Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd Sun Pharma gets observation from USFDA for Gujarat plant
Drug major Sun Pharma on Monday said it has received one observation from the US health regulator for its Baska manufacturing facility in Gujarat. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Sun Pharmaceutical Industries Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Sun Pharmaceutical Industries Ltd with reference to the media report, "Sun Pharma falls 1% on USFDA observation for Baska facility".Sun Pharmaceutical Industries Ltd response is enclosed. How a note cost India's biggest drug-maker Rs 20K cr? Hunt on
How a note cost India's biggest drug-maker Rs 20K cr? Hunt onAs per Sun Pharma, a fake note resulted in an erosion of its market capitalisation by Rs 20,000 cr in Dec. Sun Pharmaceutical Industries Ltd - 524715 - Clarification sought from Sun Pharmaceutical Industries Ltd
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd with respect to news article appearing on www.moneycontrol.com March 22, 2019, titled "Sun Pharma falls 1% on USFDA observation for Baska facility".The reply is awaited. Dry eye drug controversy:'Deal completed with satisfactory due diligence', says Sun Pharma
Away from whistle-blower allegations in India, drugmaker Sun Pharmaceutical Industries Ltd is faced with another problem involving an opthalmology dru Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
This is to inform you that the wholly owned subsidiary of the Company has increased its shareholding in PJSC Biosintez, Russia, by way of purchase of 33958 shares (30221 ordinary shares and 3737 preferred shares) equivalent to 11.86% of PJSC Biosintez under Mandatory Tender Offer. Post completion of this purchase of shares, the total holding of wholly owned subsidiary company was increased from 85.10% to 96.96% in PJSC Biosintez. The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as per 'Annexure A'.